CompletedPhase 1NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Studying T-cell prolymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TG Therapeutics, Inc.
- Principal Investigator
- Howard Burris, MD, FACPSCRI Development Innovations, LLC
- Intervention
- TGR-1202(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2018
Study locations (7)
- TG Therapeutics Trial Site, Sarasota, Florida, United States
- TG Therapeutics Trial Site, Hackensack, New Jersey, United States
- TG Therapeutics Trial Site, New York, New York, United States
- TG Therapeutics Trial Site, Durham, North Carolina, United States
- TG Therapeutics Trial Site, Cincinnati, Ohio, United States
- TG Therapeutics Trial Site, Nashville, Tennessee, United States
- TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Collaborators
SCRI Development Innovations, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01767766 on ClinicalTrials.govOther trials for T-cell prolymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06810778Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Jonsson Comprehensive Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT04629729FT819 in Subjects With B-cell MalignanciesFate Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT04684563huCART19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT04732845Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid MalignanciesBenjamin Tomlinson
- RECRUITINGNCT04411043Observatory of Prolymphocytic Leukemia TFrench Innovative Leukemia Organisation
- ACTIVE NOT RECRUITINGPHASE1NCT00586391CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLBaylor College of Medicine